Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder
Date: July 29, 2019
Issue #:
1577Summary:
The FDA has approved bremelanotide (Vyleesi– Amag),
a melanocortin receptor agonist, for subcutaneous
treatment of premenopausal women with acquired,
generalized hypoactive sexual desire disorder (HSDD).
Bremelanotide is not approved for use in men or
postmenopausal women. It is the second drug to
be approved in the US for this indication; flibanserin(Addyi), which was approved in 2015, was the first. (Source: The Medical Letter)
Source: The Medical Letter - June 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Addyi bremelanotide female sexual dysfunction flibanserin Vyleesi Source Type: research
Correction: Drugs for Chronic Heart Failure
Date: July 1, 2019
Issue #:
1575Summary:
In our Drugs for Chronic Heart Failure article,1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril(Entresto) with the ACE inhibitor enalapril for treatment of heart failure with reduced ejection fraction (HFrEF) characterized the dosage of enalapril as " suboptimal " . Some readers have objected to that characterization.The FDA-approved dosage of enalapril for treatment of HFrEF is 2.5-20 mg twice daily. In PARADIGM-HF, the dosage was capped at 10 mg twice daily,...
Source: The Medical Letter - June 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: ACE inhibitors ARBs Enalapril Entresto Heart Failure sacubitril Valsartan Source Type: research
Expanded Table: Drugs for Prophylaxis of Malaria (online only)
Date: July 1, 2019
Issue #:
1575Summary:
View the Expanded Table: Drugs for Prophylaxis of Malaria (Source: The Medical Letter)
Source: The Medical Letter - June 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Arakoda atovaquone/proguanil Doxycycline Malaria Malarone Mefloquine Primaquine phosphate tafenoquine Vibramycin Source Type: research
Drugs for Smoking Cessation
Date: July 15, 2019
Issue #:
1576Summary:
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support. (Source: The Medical Letter)
Source: The Medical Letter - June 11, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Bupropion Champix Chantix electronic cigarettes Habitrol NicoDerm CQ Nicorette Nicotine Nicotrol Smoking cessation Thrive Tobacco dependence Varenicline Wellbutrin Zyban Source Type: research
Expanded Table: Some Drugs for Psoriasis (online only)
Date: June 17, 2019
Issue #:
1574Summary:
View the Expanded Table: Some Drugs for Psoriasis (Source: The Medical Letter)
Source: The Medical Letter - June 10, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Acitretin Adalimumab Amjevita apremilast Betamethasone Brenzys brodalumab Calcipotriene calcipotriol Calcitriol Certolizumab Cimzia Cosentyx Cyclosporine Cyltezo Dovobet Dovonex Duobril Enbrel Enstilar Erelzi Etan Source Type: research
Cyclosporine 0.09% Solution (Cequa) for Dry Eye Disease
Date: July 29, 2019
Issue #:
1577Summary:
The FDA has approved cyclosporine 0.09% ophthalmic
solution (Cequa– Sun) to increase tear production
in patients with keratoconjunctivitis sicca (dry eye
disease).Restasis, a 0.05% cyclosporine emulsion,
was approved in the US in 2003 for the same indication. (Source: The Medical Letter)
Source: The Medical Letter - May 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Cequa Cyclosporine Dry eye disease lifitegrast Restasis Verkazia Xiidra Source Type: research
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
Date: July 1, 2019
Issue #:
1575Summary:
The FDA has approvedBijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketingBijuva as " the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule " . (Source: The Medical Letter)
Source: The Medical Letter - May 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Activella Alora Angeliq bazedoxifene Bijuva Bioidentical Hormones Climara Combi-Patch Divigel Drospirenone Duavee Elestrin Estrogens Evamist femhrt Femring Hot flashes Medroxyprogesterone Menest Menopause Premarin Source Type: research
Colorectal Cancer Screening
Date: July 1, 2019
Issue #:
1575Summary:
Most colorectal cancers arise from localized
adenomatous polyps in a process that may take
10 years or more. Early detection and removal of
a precancerous colonic lesion (polyp) can prevent
cancer from developing. (Source: The Medical Letter)
Source: The Medical Letter - May 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: bowel preparation Cancer screening Cologuard Colonoscopy colorectal cancer Source Type: research
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
Date: June 3, 2019
Issue #:
1573Summary:
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation (Source: The Medical Letter)
Source: The Medical Letter - May 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: amitiza Constella Constipation linaclotide Linzess lubiprostone Motegrity plecanatide prucalopride Resotran Trulance Source Type: research
Tafenoquine (Arakoda; Krintafel) for Malaria
Date: July 1, 2019
Issue #:
1575Summary:
The oral antimalarial tafenoquine succinate, a long-acting
analog of primaquine, has been approved by
the FDA in 2 different strengths.Arakoda (100-mg
tablets; Sixty Degrees) is indicated for the prophylaxis
of malaria in adults.Krintafel (150-mg tablets; GSK) is
indicated for the prevention of relapse (radical cure)
ofPlasmodium vivax malaria in patients≥16 years old
undergoing treatment for acuteP. vivax infection. (Source: The Medical Letter)
Source: The Medical Letter - May 15, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Arakoda atovaquone/proguanil Doryx Doxycycline Insect repellents Krintafel Malaria Malarone Mefloquine Primaquine phosphate tafenoquine Source Type: research
Risankizumab (Skyrizi) for Psoriasis
Date: June 3, 2019
Issue #:
1573Summary:
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi– Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist to
be approved for this indication; guselkumab(Tremfya)
and tildrakizumab(Ilumya) were approved earlier. (Source: The Medical Letter)
Source: The Medical Letter - May 15, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Acitretin Adalimumab apremilast brodalumab Calcipotriene calcipotriol Certolizumab Cimzia corticosteroids Cosentyx Cyclosporine Dovonex Enbrel Etanercept guselkumab Humira Ilumya Inflectra Infliximab ixekizumab Meth Source Type: research
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
Date: June 3, 2019
Issue #:
1573Summary:
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity– Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years. (Source: The Medical Letter)
Source: The Medical Letter - May 15, 2019 Category: Drugs & Pharmacology Authors: admin Tags: amitiza Bisacodyl Constella Constipation dulcolax linaclotide Linzess lubiprostone Miralax Motegrity plecanatide Polyethylene Glycol prucalopride Resotran Restoralax Tegaserod Trulance Zelnorm Source Type: research
Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
Date: May 20, 2019
Issue #:
1572Summary:
The FDA has approved emicizumab-kxwh (Hemlibra–
Genentech), a subcutaneously injected, factor IXa- and
X-directed antibody, for routine prophylaxis to
prevent or reduce bleeding episodes in patients with
hemophilia A. Emicizumab is not recommended for
treatment of bleeding. (Source: The Medical Letter)
Source: The Medical Letter - May 10, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Beriplex Eloctate emicizumab Hemlibra Hemophilia Source Type: research
Romosozumab (Evenity) for Postmenopausal Osteoporosis
Date: June 3, 2019
Issue #:
1573Summary:
The FDA has approved romosozumab-aqqg (Evenity–
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
R omosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) re...
Source: The Medical Letter - May 1, 2019 Category: Drugs & Pharmacology Authors: admin Tags: abaloparatide Aclasta Actonel Alendronate Atelvia Binosto Bisphosphonates Boniva Denosumab Evenity Evista Forteo Fosamax Fosavance Ibandronate Osteoporosis Postmenopausal osteoporosis Prolia Raloxifene Reclast rised Source Type: research
Inhaled Levodopa (Inbrija) for Parkinson's Disease
Date: May 20, 2019
Issue #:
1572Summary:
The FDA has approvedInbrija (Acorda), an orally
inhaled dry-powder formulation of levodopa, for
intermittent treatment of " off " episodes in patients
with Parkinson ' s disease (PD) being treated with
carbidopa/levodopa (Sinemet, and others). (Source: The Medical Letter)
Source: The Medical Letter - May 1, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Apokyn Apomorphine Carbidopa/levodopa Duopa Inbrija Movapo Parkinson ' s disease Rytary Sinemet Source Type: research
